| Bioactivity | Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of RANKL (TNFSF11). Denosumab can reduce the risk of vertebral, nonvertebral and hip fractures[1], also has anti-cancer activity[2]. |
| Name | Denosumab |
| CAS | 615258-40-7 |
| Formula | C6404H9908N1724O2004S50 |
| Molar Mass | 144716.86 |
| Appearance | Liquid |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Moen MD, et al. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63-82. [2]. Chawla S, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(12):1719-1729. |
Denosumab
CAS: 615258-40-7 F: C6404H9908N1724O2004S50 W: 144716.86
Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of RANKL (TNFSF11). Denosuma
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.